Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) EBITDA: 2017-2025

Historic EBITDA for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to -$14.5 million.

  • Aclaris Therapeutics' EBITDA fell 116.53% to -$14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$141.5 million, marking a year-over-year decrease of 299.20%. This contributed to the annual value of -$131.9 million for FY2024, which is 50.37% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported EBITDA of -$14.5 million as of Q3 2025, which was up 5.73% from -$15.4 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' EBITDA ranged from a high of -$468,000 in Q4 2023 and a low of -$96.9 million during Q4 2024.
  • Over the past 3 years, Aclaris Therapeutics' median EBITDA value was -$15.4 million (recorded in 2025), while the average stood at -$24.0 million.
  • Per our database at Business Quant, Aclaris Therapeutics' EBITDA spiked by 98.27% in 2023 and then tumbled by 20,601.28% in 2024.
  • Quarterly analysis of 5 years shows Aclaris Therapeutics' EBITDA stood at -$23.0 million in 2021, then dropped by 17.55% to -$27.1 million in 2022, then skyrocketed by 98.27% to -$468,000 in 2023, then plummeted by 20,601.28% to -$96.9 million in 2024, then tumbled by 116.53% to -$14.5 million in 2025.
  • Its EBITDA stands at -$14.5 million for Q3 2025, versus -$15.4 million for Q2 2025 and -$14.7 million for Q1 2025.